

## CURRICULUM VITÆ

**COGNOME:** Mondelli.  
**NOME:** Mario Umberto.  
**CODICE FISCALE:** MND MMB 54E29 F205L  
**RESIDENZA:** via Vitali 1, 20122 Milano. Tel: 02-796078; Fax 0382/526450  
e.mail: [m.mondelli@smatteo.pv.it](mailto:m.mondelli@smatteo.pv.it); [mario.mondelli@unipv.it](mailto:mario.mondelli@unipv.it)  
**DATA DI NASCITA:** 29 maggio 1954  
**STATO CIVILE:** coniugato, 3 figli.  
**NAZIONALITA':** Italiana.

### TITOLI:

- Dottore in Medicina e Chirurgia (con lode), 1978, Università di Milano.
- Specialista in Malattie dell'Apparato Digerente (con lode), 1982, Università di Milano.
- Dottore di Ricerca in Medicina Preventiva e di Comunità, 1988, Università di Pavia.
- Specialista in Allergologia ed Immunologia Clinica, 1991, Università di Milano.
- Professore Associato di Malattie Infettive, 1992, Università di Pavia.
- Professore Straordinario di Malattie Infettive, 2001, Università di Pavia.
- Professore Ordinario di Malattie Infettive, 2004, Università di Pavia.

### ESPERIENZE DI LAVORO.

- *Settembre 1978-Febbraio 1979.* Medico Interno, Clinica Medica III, Università di Milano.
- *Marzo 1979-Aprile 1980.* Tirocinante Ospedaliero e Medico Interno, Clinica Medica I e Scuola di Specializzazione in Malattie dell'Apparato Digerente, Ospedale Maggiore, Università di Milano.
- *Maggio 1980-Agosto 1980.* Rusconi Fellow, The Liver Unit, King's College Hospital and Medical School, Londra, Inghilterra.
- *Settembre 1980-Agosto 1981.* Titolare di Borsa di Studio assegnata con provvedimento rettorale dell'Università di Pavia, usufruita a The Liver Unit, King's College Hospital and Medical School, Londra, Inghilterra.
- *Settembre 1981-Settembre 1982.* Rusconi Fellow e titolare di borsa di studio del Consiglio Nazionale delle Ricerche (CNR), The Liver Unit, King's College Hospital and Medical School, Londra, Inghilterra.
- *Ottobre 1982-Ottobre 1984.* Cystic Fibrosis Research Fellow and Honorary Registrar, The Liver Unit, King's College Hospital and Medical School, Londra, Inghilterra.

- *Novembre 1984-Novembre 1987.* Dottorato di Ricerca in Medicina Preventiva e di Comunità, titolo conseguibile: Scienze Infettivologiche, presso l'Istituto di Clinica delle Malattie Infettive dell'Università di Pavia.

- *Novembre 1985-Dicembre 1988.* John E. Fogarty Public Health Service International Research Fellow and Visiting Investigator, Department of Basic and Clinical Research (poi Department of Molecular and Experimental Medicine), Research Institute of Scripps Clinic, Scripps Clinic and Research Foundation, La Jolla, California, USA.

- *Gennaio 1989-Dicembre 1991.* Titolare di Borsa di Studio Regionale per Ricerca Finalizzata: "Aspetti immunologici dell'infezione da HIV", Istituto di Clinica delle Malattie Infettive, Università di Pavia, I.R.C.C.S. Policlinico San Matteo, Pavia.

- *Novembre 1992-Settembre 2001.* Professore Associato di Malattie Infettive, Università di Pavia, Istituto di Clinica delle Malattie Infettive, I.R.C.C.S. Policlinico San Matteo, Pavia.

- *Ottobre 2001-Settembre 2004.* Professore Straordinario di Malattie Infettive, Università degli Studi di Pavia, Dipartimento di Malattie Infettive, IRCCS Policlinico San Matteo.

- *Gennaio 1997-.* Dirigente Medico di II livello, Direttore Laboratori Sperimentali di Ricerca-Area Infettivologica, IRCCS Policlinico San Matteo, Pavia.

- *Ottobre 2004-:* Professore Ordinario di Malattie Infettive, Università degli Studi di Pavia, Dipartimento di Malattie Infettive, IRCCS Policlinico San Matteo.

#### **MEMBRO DELLE SEGUENTI ASSOCIAZIONI.**

- Società Italiana di Malattie Infettive e Tropicali.
- New York Academy of Sciences.
- American Association of Immunologists.
- American Society for Microbiology.
- Associazione Italiana per lo Studio del Fegato.
- European Association for the Study of the Liver.
- American Association for the Study of Liver Diseases.

#### **RICONOSCIMENTI E CARICHE INTERNAZIONALI**

- 1994-99: Membro del Comitato Scientifico della European Association for the Study of the Liver (EASL).
- 1995-97: Segretario Scientifico della European Association for the Study of the Liver (EASL).
- 1997-99: Segretario Amministrativo della European Association for the Study of the Liver (EASL).
- 1995-00: Membro del Consiglio della United European Gastroenterology Federation (UEGF).

- 1999: Vice-Presidente della United European Gastroenterology Federation (UEGF).
- 2000: Presidente della United European Gastroenterology Federation (UEGF).
- 1996-2000: Membro del Consiglio della International Association for the Study of the Liver (IASL).
- 2001: Vice-Presidente della United European Gastroenterology Federation (UEGF).
- 2004- : Membro rappresentante l'Italia, Union Européenne des Médecins Specialistes, sezione Infectious Diseases (UEMS-ID).
- 2011 : Presidente Eletto della International Association for the Study of the Liver (IASL).
- 2009-2014: Presidente della UEMS-ID.
- 2009 : Fellow of the Royal College of Physicians

#### **ATTIVITA' EDITORIALE.**

Il Prof. Mario Mondelli ha prestato opera di *referee* per le seguenti riviste:

- Gastroenterology
- Hepatology
- Journal of Hepatology
- Liver International
- Gut
- Digestive and Liver Disease
- Infection
- Hybridoma
- European Journal of Clinical Investigation
- Journal of Clinical Microbiology
- Haematologica
- Journal of Viral Hepatitis
- Journal of Virology
- Digestion
- Journal of Medical Virology
- Journal of Clinical Investigation

1991-1999: Membro, **Editorial Board**, *Journal of Hepatology* (organo ufficiale della European Association for the Study of the Liver)

1999-2004 : **Associate Editor**, *Journal of Hepatology*.

1993- : Membro, **Editorial Board**, *Le Infezioni in Medicina*.

1999- : Membro, **Editorial Board**, *TTM-Hepatology*.

2001-2004: Membro, **Editorial Board**, *Digestive and Liver Disease*

2005-2009: **Co-Editor**, *Journal of Hepatology*

Revisore di progetti di ricerca per i seguenti enti di ricerca nazionali ed internazionali:

- Unione Europea Biomed 3
- MURST (ora MIUR)
- The Israel Science Foundation
- The Health Research Board of Ireland
- The Wellcome Trust
- Institut Pasteur

### **ATTIVITA' DIDATTICA.**

In qualità di docente di ruolo, il Prof. Mario Umberto Mondelli ha esercitato senza soluzione di continuità l'insegnamento nel Corso Integrato di Malattie Infettive del Corso di Laurea in Medicina dell'Ateneo pavese dall'anno accademico 1993-1994, e dall'anno accademico 2003-2004 nel Corso Integrato di Biotecnologie in Malattie Infettive nel Corso di Laurea Specialistica in Biotecnologie, dell'Università degli Studi di Pavia. Nell'ambito di un rapporto di lavoro a tempo pieno, il Prof. Mondelli ha svolto regolarmente il ciclo di lezioni formali ed esercitazioni pratiche secondo quanto concordato con il Coordinatore del Corso Integrato di Malattie Infettive. A sua volta egli è coordinatore degli insegnamenti clinici del II anno di Corso di Laurea Specialistica in Biotecnologie oltre che del Corso Integrato di Biotecnologie in Malattie Infettive nello stesso Corso di Laurea. Dall'anno accademico 1998-99 è inoltre docente nelle Scuole di Specializzazione in Medicina Interna e in Medicina Tropicale, dal 2000-01 nella Scuola di Specializzazione in Gastroenterologia e dal 2003 nella Scuola di Specializzazione in Microbiologia. Esercita personalmente attività di supervisione di studenti di medicina e specializzandi in malattie infettive nella stesura di tesi di laurea e di specialità, rispettivamente. Inoltre, il Prof. Mondelli tiene lezioni e seminari in numerose Scuole di Specializzazione nazionali ed è stato docente in corsi di perfezionamento e seminari tenutisi in Università e Istituti di Ricerca esteri, come riportato nell'elenco allegato al *curriculum vitae*. Il Prof. Mondelli partecipa regolarmente alle sessioni di esami del Corso Integrato di Malattie Infettive, agli esami di profitto e di ammissione alla Scuola di Specializzazione in Malattie Infettive e, in qualità di relatore e correlatore, agli esami di Laurea in Medicina e Chirurgia. Egli è inoltre responsabile della formazione scientifica e clinica di un gruppo di specializzandi in Malattie Infettive secondo quanto concordato con il Direttore della Scuola. Il rendiconto dell'attività didattica espletata è comunque verificabile attraverso i registri delle lezioni regolarmente compilati e consegnati presso la Presidenza di Medicina dell'Università degli Studi di Pavia e presso gli uffici universitari competenti.

## ATTIVITA' ASSISTENZIALE.

L'attività assistenziale del Prof. Mario U. Mondelli è stata intensa e varia. Nel campo specifico della Malattie Infettive si è dedicato prevalentemente all'assistenza dei pazienti epatopatici acuti e cronici e relativi problemi infettivologici. L'attività clinica si è concretizzata anche in attività di ricerca attraverso il coordinamento e la partecipazione attiva a studi clinici controllati in pazienti con epatite cronica da HCV, tenendo contemporaneamente tre sedute ambulatoriali settimanali e partecipando alla gestione clinica dei pazienti ricoverati presso il Dipartimento di Malattie Infettive, utilizzando la casistica clinica anche a scopo didattico. In qualità di Direttore (Dirigente Medico di II livello) dell'Area di Ricerca Infettivologica, una delle quattro aree tematiche di ricerca dell'IRCCS Policlinico San Matteo, ha continuato a svolgere compiti di coordinamento e promozione della ricerca nell'area infettivologica essendo inoltre responsabile della rendicontazione e programmazione scientifica, di concerto con il Direttore Scientifico dell'IRCCS, presso il Ministero della Sanità. Attualmente è responsabile di un organico di 10 persone: 4 dirigenti medici di I livello, 3 dirigenti biologi di I livello e 3 tecnici di laboratorio biomedico.

## **PUBBLICAZIONI SU RIVISTE INTERNAZIONALI SOGGETTE A PEER REVIEW**

- 1) Eddleston ALWF, **Mondelli M**, Mieli-Vergani G, Williams R. Lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection. *Hepatology* 1982;2:122S-7S.
- 2) **Mondelli M**, Mieli-Vergani G, Alberti A, Vergani D, Portmann B, Eddleston ALWF, Williams R. Specificity of T-lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. *J Immunol* 1982;129:2773-8.
- 3) **Mondelli M**, Eddleston ALWF. Lymphocyte cytotoxicity for autologous hepatocytes. *Gut* 1984;25:109-13.
- 4) Naumov NV, **Mondelli M**, Alexander GJM, Tedder RS, Eddleston ALWF, Williams R. Relationship between expression of HBV antigens in isolated hepatocytes and autologous lymphocyte cytotoxicity in patients with chronic HBV infection. *Hepatology* 1984;4:63-8.
- 5) **Mondelli M**, Mieli-Vergani G, Eddleston ALWF, Williams R, Mowat AP. Lymphocyte cytotoxicity to autologous hepatocytes in  $\alpha_1$ -antitrypsin deficiency. *Gut* 1984;25:1044-9.
- 6) **Mondelli M**, Eddleston ALWF. Mechanisms of liver cell injury in acute and chronic hepatitis B. *Semin Liver Dis* 1984;4:47-58.

- 7) Bianchi PA, **Mondelli M**, Quarto di Palo F, Ranzi T. Cyclosporin for Crohn's disease. *Lancet* 1984;*i*:1242 (letter).
- 8) **Mondelli M**, Mieli-Vergani G, Bortolotti F, Cadrobbi P, Portmann B, Alberti A, Realdi G, Eddleston ALWF, Mowat AP. Different mechanisms responsible for cell-mediated cytotoxicity to autologous hepatocytes in children with autoimmune and HBsAg positive chronic liver disease. *J Pediatr* 1985;*106*:899-906.
- 9) **Mondelli M**, Alberti A, Tremolada F, Williams R, Eddleston ALWF, Realdi G. In vitro cell-mediated cytotoxicity for autologous liver cells in chronic non-A, non-B hepatitis. *Clin Exp Immunol* 1986;*63*:147-55.
- 10) Alexander GJM, **Mondelli M**, Naumov NV, Nouri-Aria KT, Lowes D, Vergani D, Eddleston ALWF, Williams R. Functional characterization of peripheral blood mononuclear cells in chronic hepatitis B. *Clin Exp Immunol* 1986;*63*:498-507.
- 11) Chemello L, **Mondelli M**, Bortolotti F, Schiavon E, Pontisso P, Alberti A, Rondonelli EG, Realdi G. Natural killer activity in acute viral hepatitis. *Clin Exp Immunol* 1986;*64*:59-64.
- 12) **Mondelli M**, Alberti A, Rondonelli EG, Realdi G, Eddleston ALWF.  $\alpha$ -interferon enhances non-T cell cytotoxicity for autologous hepatocytes in acute and chronic HBV infection. *J Hepatol* 1986;*3*:S279-S281.
- 13) **Mondelli M**, Tedder RS, Ferns B, Pontisso P, Realdi G, Alberti A. Differential distribution of hepatitis B core and e antigens in hepatocytes: analysis by monoclonal antibodies. *Hepatology* 1986;*6*:199-204.
- 14) Eddleston ALWF, **Mondelli M**. Immunopathological aspects of liver cell injury in chronic hepatitis B virus infection. *J Hepatol* 1986;*3*:S17-S23.
- 15) **Mondelli MU**, Alberti A, Realdi G, Rondonelli EG. In vitro effect of lymphoblastoid  $\alpha$ -interferon on subpopulations of effector cells mediating cytotoxicity for autologous hepatocytes in hepatitis B and non-A, non-B. *Int J Immunopharmac* 1986;*8*:887- 91.
- 16) **Mondelli MU**, Bortolotti F, Pontisso P, Rondonelli EG, Williams R, Realdi G, Alberti A, Eddleston ALWF. Definition of hepatitis B virus (HBV)-specific target antigens recognized by cytotoxic T cells in acute HBV infection. *Clin Exp Immunol* 1987;*68*:242-50.
- 17) Ferrari C, **Mondelli MU**, Penna A, Fiaccadori F, Chisari FV. Functional characterization of cloned intrahepatic, hepatitis B virus nucleoprotein-specific helper T-cell lines. *J Immunol* 1987;*139*:539-44.
- 18) Vergani D, Mieli-Vergani G, **Mondelli M**, Portmann B, Eddleston ALWF. Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. *Liver* 1987;*7*:307-15.
- 19) **Mondelli MU**, Manns M, Ferrari C. Does the immune response play a role in the pathogenesis of chronic liver disease? *Arch Pathol Lab Med* 1988;*112*:489-97.

- 20) Ceroni M, Minoli L, Di Perri G, Senaldi G, Marone P, Achilli G, **Mondelli MU**, Camana C. Detection of HTLV-III specific IgG in the CSF from a patient with AIDS and encephalitis. *Neurology* 1988;38:143-4.
- 21) Ferrari C, Chisari FV, Ribera E, Penna A, **Mondelli MU**. Functional modulation of hepatitis B core antigen-specific T lymphocytes by an autoreactive T cell clone. *J Immunol* 1988;141:1155-60.
- 22) Raney AK, Milich DR, Hughes JL, Sorge J, Chisari FV, **Mondelli MU**, McLachlan A. Retroviral-mediated transfer and expression of hepatitis B e antigen in human skin fibroblasts and Epstein-Barr virus-transformed B lymphocytes. *Virology* 1989;168:31-9.
- 23) **Mondelli MU**, Barbarini G, Carugno B, Rondanelli EG. Absence of antibodies to human immunodeficiency virus in long-term institutionalized psychiatric patients. *Eur J Epidemiol* 1989;5:263-4 (letter).
- 24) Chisari FV, Ferrari C, **Mondelli MU**. Hepatitis B virus structure and biology. *Microb Pathogen* 1989;6:311-25.
- 25) **Mondelli MU**, Chisari FV, Ferrari C. The cellular immune response to nucleocapsid antigens in hepatitis B virus infection. *Springer Semin Immunopathol* 1990;12:25-32.
- 26) Dussaix E, Maggiore G, De Giacomo C, **Mondelli M**, Martres P, Alvarez F. Autoimmune hepatitis in children and hepatitis C virus testing. *Lancet* 1990;335:1160-1 (letter).
- 27) **Mondelli MU**, Cristina G, Filice G, Rondanelli EG, Piazza V, Barbieri C. Anti-HCV positive patients in dialysis units? *Lancet* 1990;336:244 (letter).
- 28) **Mondelli MU**. Effect of interleukin-4 on cytolytic T cells. *Int J Immunopathol Pharmacol* 1991;4:39-45.
- 29) **Mondelli MU**, Colombo M. The emerging picture of hepatitis C. *Dig Dis* 1991;9:245-252.
- 30) **Mondelli MU**, Smedile V, Piazza V, Villa G, Barbieri C, Gattarello G, Mancini F, Raimondo G. Abnormal alanine aminotransferase activity reflects exposure to hepatitis C virus in haemodialysis patients. *Nephrol Dial Transplant* 1991;6:480-3.
- 31) Cerino A, **Mondelli MU**. Identification of an immunodominant B-cell epitope on the hepatitis C virus non structural region defined by human monoclonal antibodies. *J Immunol* 1991;147:2692-6.
- 32) **Mondelli MU**, Cristina G, Piazza V, Cerino A, Villa G, Salvadeo A. High prevalence of antibodies to hepatitis C virus in haemodialysis units using a 2nd generation assay. *Nephron* 1992;61:350-1.
- 33) de Lalla C, Cerino A, Rosa C, Griva S, Bonelli F, **Mondelli MU**. Properties of a human monoclonal antibody specific for the hepatitis C virus NS4 region. *J Hepatol* 1993;18:163-7.
- 34) **Mondelli MU**, Cerino A, Bellotti V, de Koning A. Immunobiology and pathogenesis of hepatitis C virus infection. *Res Virol* 1993;144:269-74.

- 35) Maccabruni A, Caselli D, **Mondelli M**, Degioanni M, Cerino A. Vertical transmission of hepatitis C virus and HIV. *AIDS* 1993;7:1024-5 (letter).
- 36) Silini E, Bono F, Cerino A, Piazza V, Solcia E, **Mondelli MU**. Virological features of HCV infection in hemodialysis patients. *J Clin Microbiol* 1993;31:2913-7.
- 37) Cerino A, Boender P, Rosa C, La Monica N, Habets W, **Mondelli MU**. A human monoclonal antibody specific for the N-terminus of hepatitis C virus nucleocapsid protein. *J Immunol* 1993;151:7005-15.
- 38) González-Peralta RP, Fang JWS, Davis GL, Gish R, Tsukiyama-Kohara K, Kohara M, **Mondelli MU**, Lesniewski R, Phillips MI, Mizokami M, Lau JYN. Optimization for the detection of hepatitis C virus (HCV) antigens in the liver. *J Hepatol* 1994;20:143-7.
- 39) **Mondelli MU**, Cerino A, Boender P, Oudshoorn P, Middeldorp J, Fipaldini C, La Monica N, Habets W. Significance of the immune response to a major, conformational B cell epitope on the hepatitis C virus NS3 region defined by a human monoclonal antibody. *J Virol* 1994;68:4829-36.
- 40) **Mondelli MU**, Cerino A, Bono F, Cividini A, Malfitano A, Maccabruni A, Barbarini G, Aricò M, Piazza V, Minoli L, Silini E. Hepatitis C virus (HCV) core serotypes in chronic HCV infection. *J Clin Microbiol* 1994;32:2523-7.
- 41) Aricò M, Maggiore G, Silini E, Bono F, Viganò C, Cerino A, **Mondelli MU**. Hepatitis C virus infection in children treated for acute lymphoblastic leukemia. *Blood* 1994;84:2919-22.
- 42) Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, Belloni G, Brugnetti B, Civardi E, Salvaneschi L, **Mondelli MU**. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. *Hepatology* 1995;21:285-90.
- 43) Maggiore G, Ventura A, De Giacomo C, Silini E, Cerino A, **Mondelli MU**. Vertical transmission of hepatitis C. *Lancet* 1995;345:1122 (letter).
- 44) Silini E, Bono F, Cividini A, Cerino A, Bruno S, Maccabruni A, Tinelli C, Bellobuono A, **Mondelli MU**. Molecular epidemiology of hepatitis C virus infection in intravenous drug users. *J Hepatol* 1995;22:691-5.
- 45) Scarselli E, Cerino A, Esposito G, Silini E, **Mondelli MU**, Traboni C. Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (E2; gp70) hypervariable region 1 in hepatitis C viremic patients. *J Virol* 1995;69:4407-12.
- 46) **Mondelli MU**, Cividini A, Cerino A. Role of humoral immune responses in hepatitis B and C virus infections. *Eur J Clin Invest* 1995;25:543-7.
- 47) Maccabruni A, Bossi G, Caselli D, Cividini A, Silini A, **Mondelli MU**. High efficiency of transmission of hepatitis C virus among babies born to human immunodeficiency virus-negative women. *Pediatr Infect Dis J* 1995;14:921-2 (letter).
- 48) Esposito G, Scarselli E, Cerino A, **Mondelli MU**, La Monica N, Traboni C. A human antibody specific for the hepatitis C virus core protein: expression in a bacterial system and characterization. *Gene* 1995;164:203-9.



- 49) González-Peralta RP, Fang JWS, Davis GL, Gish RG, Kohara M, **Mondelli MU**, Urdea MS, Mizokami M, Lau JYN. Significance of hepatic expression of hepatitis C viral antigens in chronic hepatitis C. *Digest Dis Sci* 1995;40:2595-601.
- 50) Silini E, **Mondelli MU**. Significance of hepatitis C virus genotypes. *Vir Hepat Rev* 1995;1:111-20.
- 51) Gane EJ, Naoumov NV, Qian K-P, **Mondelli MU**, Maertens G, Portmann BC, Lau JYN, Williams R. A longitudinal analysis of hepatitis C virus replication following liver transplantation. *Gastroenterology* 1996;110:167-77.
- 52) Cerino A, Cividini A, Asti M, Lanza A, Silini E, **Mondelli MU**. Comparative evaluation of two serologic typing methods of hepatitis C virus. *J Clin Microbiol* 1996;34:714-6.
- 53) **Mondelli MU**. Is there a role for immune responses in the pathogenesis of hepatitis C? *J Hepatol* 1996; 25:232-8.
- 54) Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, Bono F, Iamoni G, Tinelli C, **Mondelli MU**, Ideo G. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. *Gastroenterology* 1996;111:199-205.
- 55) Cerino A, Bissolati M, Cividini A, Nicosia A, Esumi M, Hayashi N, Mizuno K, Slobbe R, Oudshoorn P, Silini E, Asti M, **Mondelli MU**. Antibody responses to the hepatitis C virus (HCV) E2 protein: relationship to viraemia and prevalence in anti-HCV seronegative subjects. *J Med Virol* 1997;51:1-5.
- 56) Esposito G, Morea V, Scarselli E, Cerino A, **Mondelli MU**, La Monica N, Traboni C. Recombinant human antibodies specific for hepatitis C virus proteins. *Arch Virol* 1997;142:601-10.
- 57) Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Larghi A, Cerino A, Podda M, **Mondelli MU**. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. *Hepatology* 1997;25:754-8.
- 58) Tafi R, Bandi R, Prezzi C, **Mondelli MU**, Cortese R, Monaci P, Nicosia A. Identification of HCV core mimotopes: improved methods for the selection and use of disease-related phage-displayed peptides. *Biol Chem* 1997;378:495-502.
- 59) Cividini A, Pistorio A, Regazzetti A, Cerino A, Tinelli C, Mancuso A, Ribola M, Galli ML, Agnusdei A, Leone M, Silini E, **Mondelli MU**. Hepatitis C virus infection among institutionalized psychiatric patients: a regression analysis of indicators of risk. *J Hepatol* 1997;27:455-63.
- 60) Cristina G, Piazza V, Efficace E, Poggio F, Pasotti N, Martino G, Cividini A, Salvadeo A, **Mondelli MU**. A survey of hepatitis C virus infection in haemodialysis patients over a 7-year follow-up. *Nephrol Dial Transplant* 1997;12:2208-10 (letter).
- 61) Zavaglia C, Martinetti M, Silini E, Bottelli R, Daielli C, Asti M, Salvaneschi L, **Mondelli MU**, Ideo G. Association between class II alleles and protection or susceptibility to chronic hepatitis C. *J Hepatol* 1998;28:1-7.

- 62) Brambilla S, Bellati G, Asti M, Lisa A, Candusso ME, D'Amico M, Grassi G, Giacca M, Franchini A, Bruno S, Ideo G, **Mondelli MU**, Silini E. Dynamics of hypervariable region 1 (HVR1) variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. *Hepatology* 1998;27:1678-86.
- 63) Puntoriero G, Meola A, Lahm A, Zucchelli S, Bruno B, Tafi R, Pezzanera M, **Mondelli MU**, Cortese R, Tramontano A, Galfrè G, Nicosia A. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. *EMBO J* 1998;17:3521-33.
- 64) Silini E, Belli L, Alberti AB, Asti M, Cerino A, Bissolati M, Rondinara G, De Carlis L, Forti D, **Mondelli MU**, Ideo G. HGV/GBV-C infection in liver transplant recipients. Antibodies to the viral E2 envelope glycoprotein protect from *de novo* infection. *J Hepatol* 1998;29:533-40.
- 65) Maggiore G, Caprai S, Cerino A, Silini E, **Mondelli MU**. Antibody-negative chronic hepatitis C virus infection in immunocompetent children. *J Pediatr* 1998;132:1048-50.
- 66) **Mondelli MU**, Zorzoli I, Cerino A, Cividini A, Bissolati M, Segagni L, Perfetti V, Anesi E, Garini P, Merlini GP. Clonality and specificity of cryoglobulins associated with HCV: pathophysiological implications. *J Hepatol* 1998;29:879-86.
- 67) Aricò M, Bissolati M, Bossi G, Asti M, Cerino A, Caselli D, Ricci A, Klersy C, Silini E, **Mondelli MU**. GB virus C infection in patients treated for childhood acute lymphoblastic leukemia. *Transfusion* 1999;39:212-7.
- 68) Negro F, Krawczynski K, Quadri R, Rubbia-Brandt L, **Mondelli MU**, Zarski J-P, Hadengue A. Detection of genomic and minus strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semi-quantitative RT-PCR. *Hepatology* 1999;29:536-42.
- 69) Piazza V, Cristina G, Montagna G, Galli F, Ungaretti M, Martino G, Cividini A, Salvadeo A, **Mondelli MU**. Long-term persistence of hepatitis C viremia in hemodialysis patients. *Clin Nephrol* 1999;51:129-30.
- 70) Asti M, Martinetti M, Zavaglia C, Cuccia M, Gusberti L, Tinelli C, Cividini A, Bruno S, Salvaneschi L, Ideo G, **Mondelli MU**, Silini E. HLA class II and III and severity of hepatitis C virus (HCV)-related chronic liver disease. *Hepatology* 1999;29:1272-9.
- 71) Osella AR, Sonzogni L, Cavallini A, Foti L, Guerra V, Di Leo A, **Mondelli MU**, Misciagna G, Silini EM. Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in Southern Italy: a population-based study. *J Clin Microbiol* 1999;37:2371-2.
- 72) **Mondelli MU**, Cerino A, Lisa A, Brambilla S, Segagni L, Cividini A, Bissolati M, Missale G, Bellati G, Meola A, Bruniercole B, Nicosia A, Galfrè G, Silini E. Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation. *Hepatology* 1999;30:537-45.
- 73) **Mondelli MU**, Silini E. Clinical significance of hepatitis C virus genotypes. *J Hepatol* 1999;31: (Suppl.1) 65-70.

- 74) Romeo R, Rumi MG, Donato MF, Cargnel MA, Viganò P, **Mondelli MU**, Cesana B, Colombo M. Hepatitis C is more severe in drug users with human immunodeficiency virus infection. *J Viral Hepatitis* 2000;7:297-301.
- 75) **Mondelli MU**. Immunopathogenesis of viral hepatitis. *Clin Rev Allerg Immunol* 2000;18:141-166.
- 76) Raimondo G, Balsano C, Craxì A, Farinati F, Levrero M, **Mondelli MU**, Pollicino C, Squadrito G, Tiribelli C. Occult hepatitis B virus infection. *Dig Liver Dis* 2000;32:822-6.
- 77) **Mondelli MU**. Neonatal blood microtransfusions and hepatitis C virus infection. (Letter). *Lancet* 2001;357:1363.
- 78) Osella AR, Misciagna G, Elba S, Buongiorno G, Cavallini A, Di Leo A, Sonzogni L, **Mondelli MU**, Silini EM. Hepatitis C virus genotypes and risk of cirrhosis in Southern Italy. *Clin Infect Dis* 2001;33:70-5.
- 79) Piazza V, Montagna G, Galli F, Efficace E, Boselli E, Cristina G, Salvadeo A, **Mondelli MU**. Risk of exposure to hepatitis B and C viruses in hemodialysis patients: a 10-year survey. *Clin Nephrol* 2001;56:252-4.
- 80) **Mondelli MU**, Cerino A, Segagni L, Meola A, Cividini A, Silini E, Nicosia A. Hypervariable region 1 (HVR1) of HCV: Immunological decoy or biologically relevant domain? *Antiviral Res* 2001;52:153-9.
- 81) Cividini A, Rebucci C, Silini E, **Mondelli MU**. Is the natural history of hepatitis C virus carriers with normal aminotransferase really benign? *Gastroenterology* 2001;121:1526-7.
- 82) Cerino A, Meola A, Segagni L, Furione M, Triyatni M, Liang TJ, Nicosia A, **Mondelli MU**. Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles *J Immunol* 2001;167:3878-3886.
- 83) Roccasecca R, Folgori A, Ercole BB, Puntoriero G, Lahm A, Zucchelli S, Tafi R, Pezzanera M, Galfré G, Tramontano A, **Mondelli MU**, Pessi A, Nicosia A, Cortese R, Meola A. Mimotopes of the hypervariable region 1 of the hepatitis C virus induce cross-reactive antibodies directed against discontinuous epitopes. *Mol Immunol* 2001;38:485-92.
- 84) Sonzogni L, Silvestri L, De Silvestri A, Gritti C, Foti L, Zavaglia C, Battelli R, **Mondelli MU**, Civardi E, Silini EM. Polymorphisms of microsomal epoxyde hydrolase gene and severity of HCV-related liver disease. *Hepatology* 2002;36:195-201.
- 85) Sullivan DE, **Mondelli MU**, Curiel DT, Krasnykh V, Mikheeva G, Gaglio P, Morris CB, Dash S, Gerber MA. Construction and characterization of an intracellular single-chain human antibody to hepatitis C virus non-structural 3 protein. *J Hepatol* 2002;37:660-8.
- 86) Silvestri L, Sonzogni L, De Silvestri A, Gritti C, Foti L, Zavaglia C, Leverì M, Cividini A, **Mondelli MU**, Civardi E, Silini EM. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. *Int J Cancer* 2003;104:310-7.

- 87) Cividini A, Cerino A, Muzzi A, Furione M, Rebucci C, Segagni L, Gatti M, Barnaba V, **Mondelli MU**. Kinetics and significance of serum hepatitis C virus core antigen in patients with acute hepatitis C. *J Clin Microbiol* 2003;41:2144-6.
- 88) **Mondelli MU**, Cerino A, Meola A, Nicosia A. Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses. *J Biosci* 2003;28:305-10.
- 89) Rebucci C, Cerino A, Cividini A, Timo L, Furione M, **Mondelli MU**. Monitoring response to antiviral therapy in patients with chronic hepatitis C virus infection by a core antigen assay. *J Clin Microbiol* 2003;41:3881-4.
- 90) Rossi L, Levreri M, Gritti C, De Silvestri A, Zavaglia C, Sonzogni L, Silvestri L, Civardi E, **Mondelli MU**, Silini EM. Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients. *J Hepatol* 2003;39:564-70.
- 91) **Mondelli MU**. Natural history of hepatitis C virus infection. *J Biol Regul Homeost Agents* 2003;17:128-32.
- 92) **Mondelli MU**. Hepatitis C virus: simply too smart to be just a liver pathogen. *Dig Liver Dis* 2003;35:760-2.
- 93) **Mondelli MU**. Multifaceted functions of B cells in chronic hepatitis C virus infection. *Antivir Res* 2003;60:111-5.
- 94) Francavilla V, Accapezzato D, De Salvo M, Rawson P, Cosimi O, Lipp M, Cerino A, Cividini A, **Mondelli MU**, Barnaba V. Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanisms. *Eur J Immunol*, 2004;34:427-37.
- 95) Accapezzato D, Francavilla V, Rawson P, Cerino A, Cividini A, **Mondelli MU**, Barnaba V. Subversion of CD8+ T cell differentiation in acute hepatitis C virus infection: the role of the virus. *Eur J Immunol*, 2004;34:438-46.
- 96) Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A, Abrignani S, **Mondelli MU**, Barnaba V. Hepatic expansion of a virus-specific regulatory CD8+T cell population in chronic hepatitis C virus infection. *J Clin Invest* 2004;113:963-72.
- 97) **Mondelli MU**. Monitoring response to antiviral treatment by serum hepatitis C virus core antigen: too early to take shortcuts? *J Hepatol* 2004;40:536-8.
- 98) Leverì, M, Gritti C, Rossi L, Zavaglia C, Civardi E, **Mondelli MU**, De Silvestri A, Silini E. Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. *Cancer Lett* 2004;208:75-9.
- 99) Furione M, Maserati R, Gatti M, Baldanti F, Cividini A, Bruno R, Gerna G, **Mondelli MU**. Dissociation between serum and liver hepatitis C virus RNA levels in patients coinfecting with human immunodeficiency virus. *J Clin Microbiol* 2004;42:3012-6.

- 100) Bruno S, Cammà C, Di Marco V, Di Bona D, Rumi MG, Vinci M, Rebucci C, Colombo M, Craxì A, **Mondelli MU**, Pinzello GB. Peginterferon alfa2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. *J Hepatol* 2004;41:474-81.
- 101) Spada E, Mele A, Berton A, Ruggeri L, Ferrigno L, Garbuglia AR, Perrone MP, Girelli G, Del Porto P, Piccolella E, **Mondelli MU**, Amoroso P, Cortese R, Nicosia A, Vitelli A, Folgori A. Multi-specific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. *Gut* 2004;53:1673-81.
- 102) Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Malinverni R, Dufour J-F, Helbling B, Hadengue A, Gonvers J-J, Müllhaupt B, Cerny A, **Mondelli MU**, Negro F, for the Swiss Hepatitis C Cohort Study (SCCS). Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. *J Hepatol* 2005;42:41-6.
- 103) **Mondelli MU**, Cerino A, Cividini A. Acute hepatitis C: diagnosis and management. *J Hepatol*. 2005;42:S108-14.
- 104) Accapezzato D, Visco V, Francavilla V, Molette C, Donato T, Paroli M, **Mondelli MU**, Doria M, Torrisi MR, Barnaba V. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. *J Exp Med*. 2005;202:817-28.
- 105) Cammà C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, Rebucci C, Cividini A, Pizzolanti G, **Mondelli MU**, Colombo M, Pinzello G, Craxì A. Insulin resistance is associated with steatosis in non-diabetic patients with genotype 1 chronic hepatitis C. *Hepatology* 2006;43:64-71.
- 106) **Mondelli MU** and Barnaba V. Viral and host immune regulatory mechanisms in HCV infection. *Eur J Gastroenterol Hepatol*, 2006;18:327-31.
- 107) Bianchettin G, Bonaccini C, Oliva R, Tramontano A, Cividini A, Casato M, Merlini G, Silini E, **Mondelli MU**. Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls. *J Virol* 2007; 81:4564-71.
- 108) Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, **Mondelli MU**. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in cirrhotic patients: a seventeen-year, prospective cohort study. *Hepatology* 2007;46:1350-1356.
- 109) Ferraro D, Giglio M, Bonura C, Di Marco V, **Mondelli MU**, Craxì A, Di Stefano R. Assessment of HCV RNA clearance under combination therapy for HCV genotype 1: performance of the transcription-mediated amplification (TMA) assay. *J Vir Hepat* 2008; 15:66-70.
- 110) **Mondelli MU**. Eltrombopag: an effective remedy for thrombocytopaenia? *J Hepatol* 2008;48:1030-2.
- 111) Raimondo G, Allain J-P, Brunetto MR, Buendia MA, Chen D-S, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, **Mondelli MU**, Pawlotsky J-M, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trepo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the *Taormina* expert meeting on occult hepatitis B virus infection. *J Hepatol* 2008; 49:652-7.

- 112) Varchetta S, Oliviero B, Donato MF, Agnelli F, Rigamonti C, Paudice E, Arosio E, Berra M, Rossi G, Tinelli C, Fagnoni FF, Colombo M, Mavilio D, **Mondelli MU**. Prospective study of natural killer cell phenotype in recurrent hepatitis C virus infection following liver transplantation: *J Hepatol* 2009;50:314-22.
- 113) Franceschini D, Paroli M, Francavilla V, Videtta M, Morrone S, Labbadia G, Cerino A, **Mondelli MU**, Barnaba V. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. *J Clin Invest* 2009;119:551-64.
- 114) Raimondi S, Bruno S, **Mondelli MU**, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. *J Hepatol* 2009;50:1142-54.
- 115) Oliviero B, Varchetta, Paudice E, Cerino A, Michelone G, Zaramella M, Mavilio D, De Filippi F, Bruno S, **Mondelli MU**. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. *Gastroenterology* 2009;137:1151-60.
- 116) Raimondi S, Maisonneuve P, Bruno S, **Mondelli MU**. Is response to antiviral treatment influenced by hepatitis B virus genotype? *J Hepatol* 2010; 52:441-49.
- 117) **Mondelli MU**, Varchetta S, Oliviero B. Natural killer cells in viral hepatitis: facts and controversies. *Eur J Clin Invest* 2010; 40:851-63.
- 118) Oliviero B, Cerino A, Varchetta S, Paudice E, Pai S, Ludovisi S, Zaramella M, Michelone G, Pugnale P, Negro F, Barnaba V, **Mondelli MU**. Enhanced B cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. *J Hepatol* (2011), doi:10.1016/j.jhep.2010.10.016.

#### CAPITOLI PUBBLICATI SU LIBRI ESTERI.

- 1) **Mondelli M**, Naumov N, Eddleston ALWF. *The immunopathogenesis of liver damage in chronic hepatitis B virus infection*. In: Chisari FV, ed., *Advances in hepatitis research*. Masson Publishing, Inc., New York, 1984;144-51.
- 2) Fiaccadori F, **Mondelli M**, Penna A, Chisari FV, Ferrari C. *Isolation and functional characterization of circulating HBcAg-specific and autoreactive T cell clones in chronic active hepatitis B*. In: Gentilini P, Dianzani MU, eds., *Patophysiology of the liver*, Elsevier Science Publishers BV, 1988;109-17.
- 3) Ferrari C, Penna A, **Mondelli MU**, Fiaccadori F, Chisari FV. *Intrahepatic HBcAg-specific regulatory T-cell networks in chronic active hepatitis B*. In: *Viral hepatitis and liver disease*. Alan Liss, Inc., New York, 1988;641-4.
- 4) **Mondelli MU**, Parks DE, Chisari FV. *Production and distribution of lymphocytes and plasma cells*. In: Williams WJ, Beutler E, Erslev AJ, Lichtmann MA, eds., *Hematology* 4th edition. McGraw-Hill, New York, 1990;945-9.

- 5) **Mondelli MU**, Cerino A, Bellotti V, de Lalla C, Rosa C, Bonelli F, Habets W. *Production and characterization of a human monoclonal antibody to the hepatitis C virus NS4 region*. In: Terhorst C, Malavasi F, Albertini A (eds): *Generation of Antibodies by Cell and Gene Immobilization*. Year Immunol. Basel, Karger 1993;7:220-6.
- 6) **Mondelli MU**, Cerino A. *Clonal analysis of human lymphocyte-B responses to hepatitis C virus structural and non-structural regions*. In: Meyer zum Büschenfelde K-H, Hoofnagle JH, Manns M, eds. *Immunology and Liver, Proceedings of Falk Symposium No.70*, Kluwer Academic Publishers, Lancaster U.K., 1993;105-14.
- 7) **Mondelli MU**, Negro F. *Immunobiology of hepatitis B and D virus infections*. In: Thomas HC, Waters J, eds., *Immunology of liver disease*. Kluwer Academic Publishers, Dordrecht, The Netherlands, 1994;39-55.
- 8) **Mondelli MU**, Perrillo RP. Workshop: "Clinical significance of virus-specific immune responses". In: Rizzetto M, Purcell RH, Gerin JL, Verme G, Eds., "Viral Hepatitis and Liver Disease", *Proceedings of IX Triennial International Symposium on Viral Hepatitis and Liver Disease*, Rome, Italy, 21-25 April 1996. Edizioni Minerva Medica, Torino, 1997:855-7.
- 9) **Mondelli MU**, Tur-Kaspa R. Poster's summary: "Immunology – Non A-E Hepatitis". In: Rizzetto M, Purcell RH, Gerin JL, Verme G, Eds., "Viral Hepatitis and Liver Disease", *Proceedings of IX Triennial International Symposium on Viral Hepatitis and Liver Disease*, Rome, Italy, 21-25 April 1996. Edizioni Minerva Medica, Torino, 1997:919-20.
- 10) **Mondelli MU**, Cerino A. *Production of anti-HCV by human B cell clones and their characterization*. In: Lau JYN, Ed., "Hepatitis C Protocols", *Methods in Molecular Medicine*, The Humana Press Inc., Totowa U.S.A., 1998, p. 451-61.
- 11) Martinetti M, Hammer J, Asti M, Badulli C, D'Aronzo AM, Cuccia M, Moretta A, Maccario R, Ferrarotti I, **Mondelli MU**, Silini E, Cividini A, Salvaneschi L. *In vitro* T-cell immune reactivity against promiscuous frames on hepatitis C virus core protein predicted by computational analysis. In Hansen JA and Dupont BO (Editors). *HLA 2002: immunobiology of the human MHC*. IHWG press, Seattle, USA.
- 12) **Mondelli MU**, Barnaba V. Regulatory cell subsets involved in immunotolerance and immunosuppression. In: Moreno-Otero R, Albillos A, Bañares R, Cuervas-Mons V, Medina J (Eds.) *Immunology and the Liver: Immunotherapy*. Accion Medica, Madrid, Spain, 2004, pp. 3-8.
- 13) **Mondelli MU**, Cerino A, Varchetta S. Linking viral infections to autoimmunity: B-cell activation in chronic hepatitis C. *Accion Medica*, Madrid, Spain, 2006, pp. 79-86.
- 14) **Mondelli MU**, Oliviero B, Paudice E, Varchetta S, Zaramella M, Michelone G, Gulminetti R, Cerino A. Protective and damaging immune responses to hepatitis C virus. In: Buti M, Esteban R (Eds.) *Viral Hepatitis*, Barcelona 2008.
- 15) Ferrari C, **Mondelli M**. Immune mechanisms of viral clearance and disease pathogenesis during viral hepatitis. In Arias I. (Ed.), *The Liver Biology and Pathobiology*, 5<sup>th</sup> Edition, John Wiley, 2009, in press.

- 1) **Mondelli MU.** Cell-mediated immunity to HBV proteins. The Liver Unit, King's College Hospital, London, 1988.
- 2) **Mondelli MU.** Recent approaches to the analysis of the role of T cells in HBV infection. 7th International Congress of Immunology, Berlin, 1989.
- 3) **Mondelli MU.** Experimental models for the pathogenesis of HBV in man. President's premeeting, XLIV Meeting of the German Society of Gastroenterology, Mainz, 1989.
- 4) **Mondelli MU.** The cellular basis of the immune response to hepatitis B virus in man. Division of Molecular Virology, Baylor College of Medicine, Houston, 1990.
- 5) **Mondelli MU.** Significance and specificity of the immune response to HCV. Liver Disease in the 1990's, 25th anniversary scientific meeting. Institute of Liver Studies, King's College School of Medicine and Dentistry, London, 1991.
- 6) **Mondelli MU.** B-cell epitopes on hepatitis C virus. Abteilung Gastroenterologie und Hepatologie, Medizinische Hochschule, Hannover, 1992.
- 7) **Mondelli MU.** B-cell response to hepatitis C virus. Falk Symposium No. 70: Immunology and Liver, Basel Liver Week 1992, 1992.
- 8) **Mondelli MU.** Immune responses in hepatitis C. Annual Meeting of the Irish Society for Immunology. Dublin 1992.
- 9) **Mondelli MU.** *Selected posters discussant.* XXVIII Meeting of the European Association for the Study of the Liver, Paris, 1993.
- 10) **Mondelli MU.** Production and characterization of human monoclonal antibodies to hepatitis C virus. Meeting on "Biotechnology - a potent tool for basic research". Cooperation of Coimbra Group Universities, Bologna, 1995.
- 11) **Mondelli MU.** Significance and specificity of the antibody response to hepatitis C virus. Liver Unit, Hadassah University Hospital, Jerusalem 1996.
- 12) **Mondelli MU, Perrillo RP.** Breakfast session: "The clinical significance of virus-specific immune response". IX Triennial Symposium on Viral Hepatitis and Liver Disease, Roma, 1996.
- 13) **Mondelli MU.** Role of the immune system in liver damage. 2nd EASL Postgraduate Course on "Viral and immune liver damage", Szczecin, Poland, 1996.
- 14) **Mondelli MU.** HCV humoral immune response. Workshop: "HCV and host response before and after liver transplantation", Göttingen, 1996.
- 15) **Mondelli MU.** Viral heterogeneity and outcome of hepatitis C. Eli Lilly and Co., Indianapolis, IN, USA, 1997.



- 16) **Mondelli MU.** Is Hepatitis G virus a problem in paediatric hepatology? International Meeting on Paediatric Hepatology. Chronic Viral Hepatitis in Childhood: Natural History and Interferon Treatment. Sorrento, Italy, 1997.
- 17) **Mondelli MU.** Influence of viral heterogeneity on the outcome of hepatitis C. XIV Meeting of the Turkish Society of Gastroenterology, Mersin, Turkey, 1997.
- 18) **Mondelli MU.** Invited co-chairman/organiser and speaker at the Symposium “Hepatitis 1997”, 6th United European Gastroenterology Week, Birmingham, 1997.
- 19) **Mondelli MU.** Immune response to HCV: Hepatitis C: Leading-Edge Scientific and Clinical Advances, Montecarlo, Monaco, 1998.
- 20) **Mondelli MU.** Immunopathogenesis of Viral Hepatitis: EASL Postgraduate Course & First Hepatology Day, Istanbul, 1998.
- 21) **Mondelli MU.** Immune responses to HCV and viral heterogeneity. Immunology in liver disease: basis for present and future therapy. 11<sup>th</sup> World Congress of Gastroenterology. Vienna, 1998.
- 22) **Mondelli MU.** Natural history of viral hepatitis. 1<sup>st</sup> Mediterranean Summer School, Samos, Greece, 21-24, 1998.
- 23) **MU Mondelli.** Clinical implications of viral genotypes. EASL International Consensus Conference on Hepatitis C. Paris, France, 1999.
- 24) **Mondelli MU.** Does the immune response play a role in the selection of HCV variants? IX International Symposium on viral hepatitis. Madrid, 2000.
- 25) **Mondelli MU.** HCV Immunology. “Optimizing the treatment of HCV”. Schering-Plough Symposium, Madrid, 2000.
- 26) **Mondelli MU.** Significance of hepatitis C virus genotypes and variants. 8<sup>th</sup> United European Gastroenterology Week, Brussels, 2000.
- 27) **MU Mondelli.** Immune response and HCV variability. Invited seminar. Istituto di Ricerche in Biomedicina, Bellinzona, Switzerland, 2002.
- 28) **MU Mondelli.** HCV variability and antiviral immune response. 2002 International Symposium on Liver Diseases Progress, Chongqing, China, 2002.
- 29) **MU Mondelli.** Mechanism of the liver disease induced by HCV. Course “Hepatitis C virus infection”, Valencia, Spain, 2002.
- 30) **MU Mondelli.** How the host fights HCV: the immunologist’s point of view. 10<sup>th</sup> United European Gastroenterology Week, Geneva, Switzerland, 2002.
- 31) **MU Mondelli.** Variability or conservation of the hepatitis C virus hypervariable region 1? X International Symposium on Viral Hepatitis, Madrid, 2003.
- 32) **MU Mondelli.** Regulatory cell subsets involved in immunotolerance and immunosuppression. III International Symposium on Immunology and the Liver: Immunotherapy. Madrid, 2004.

- 33) **MU Mondelli.** Effects of immunosuppressive drugs on HCV and HBV. 10th International Meeting of French Study Group on Molecular Hepatology (GEMHEP), 2005.
- 34) **MU Mondelli.** Antiviral + immunodulatory agents. EASL Monothematic Conference: from Viral Pathobiology to the Treatment of Hepatitis B Virus Infection. Istanbul, 2005.
- 35) **MU Mondelli.** Predictors of disease severity: HCV. European Association for the Study of the Liver School of Hepatology, Milan, 2005.
- 36) **MU Mondelli.** Linking viral infections to autoimmunity: B-cell activation in chronic hepatitis C. IV International Meeting on Immunology and the Liver: Inflammation, Repair and Therapies, Madrid, Spain, 2006.
- 37) **MU Mondelli.** B cells. EASL Monothematic Conference: Clinical Immunology in Viral Hepatitis, London, 2006.
- 38) **MU Mondelli.** Immune response to HCV. IX International Symposium on Viral Hepatitis, Barcelona 20-21 June 2008.
- 39) **MU Mondelli.** Determinants of Disease Progression in HBV. Post Graduate Course of Hepatology organized by the Tropical Medicine Department and Hepatology Unit, Faculty of Medicine, Cairo University, 10-12 October 2009.
- 40) **MU Mondelli.** Management of Extra Hepatic Manifestations of Chronic Hepatitis C. Post Graduate Course of Hepatology organized by the Tropical Medicine Department and Hepatology Unit, Faculty of Medicine, Cairo University, 10-12 October 2009.
- 41) **MU Mondelli.** Innate and adaptive immune responses in viral hepatitis: phenotypic changes and altered function of NK and B cells. Meeting with Johns Hopkins and San Matteo, July 8-9, 2010.
- 42) **MU Mondelli.** NK cells in hepatic infections. Workshop SIICA: Innate immunity in the pathogenesis of immune-mediated human diseases. Milan, Italy, November 3-4, 2010.